Correction: Phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab for relapsed or refractory multiple myeloma

By
Adam D. Cohen
Joshua Richter
Suzanne Trudel
Alexander Lesokhin
Jacob P. Laubach
Sheeba K. Thomas
Simon J. Harrison
Luciano J. Costa
Andrew Spencer
Rafael Fonseca
Peter A. Forsberg
Jesus G. Berdeja
Rayan Kaedbey
Nizar J. Bahlis
Paula Rodriguez-Otero
Maria-Victoria Mateos
Tulika Tyagi
Divya Samineni
Wenyu Liu
Rin Nakamura
Voleak Choeurng
Chihunt Wong
James Cooper
Amrita Krishnan
October 20, 2026

Nature Medicine

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Correction
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	Patients or participants described in the source article.
Care Setting	Not specified in the correction.

Key Highlights

The correction was published online on 22 July 2026.
It concerns Extended Data Fig. 3b in both panels.
The original left x-axis label, “No 1q gain or amp,” was incorrect.
The corrected label is “1q normal.”
The correction was implemented in the HTML and PDF versions.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

The study title identifies patients with relapsed or refractory multiple myeloma; the correction provides no further patient or prescribing details.

The study concerns cevostamab, an FcRH5×CD3 bispecific antibody. The correction addresses a figure label and provides no treatment outcomes or prescribing guidance.